Retinoic acid-mediated G1-S-phase arrest of normal human mammary epithelial cells is independent of the level of p53 protein expression

Cell Growth and Differentiation

Volumn 10, Issue 1, 1999, Pages 49-59

  Seewaldt, Victoria L ^a,c   Dietze, Eric C ^b   Johnson, Barton S ^b   Collins, Steven J ^b   Parker, Molly B ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CALPASTATIN; ESTROGEN; HYDROXYTAMOXIFEN; LACTACYSTIN; PROTEASOME INHIBITOR; PROTEIN P53; RETINOIC ACID; RETINOID; TAMOXIFEN; VIRUS PROTEIN;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA DAMAGE; GENE INDUCTION; GENE TRANSFER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; WART VIRUS;

ANTIGENS, VIRAL; APOPTOSIS; BREAST; CELL CYCLE; CELL DIVISION; CELL TRANSFORMATION, VIRAL; CELLS, CULTURED; CYCLIN D1; CYSTEINE ENDOPEPTIDASES; EPITHELIAL CELLS; FEMALE; G1 PHASE; GENE EXPRESSION REGULATION; GENETIC VECTORS; HUMANS; MULTIENZYME COMPLEXES; ONCOGENE PROTEINS, VIRAL; PROTEASOME ENDOPEPTIDASE COMPLEX; REPRESSOR PROTEINS; RETROVIRIDAE; S PHASE; TRETINOIN; TUMOR SUPPRESSOR PROTEIN P53;

ATRA; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES;

EID: 0032978908     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Gudas, L. J. Retinoids, retinoid-responsive genes, cell differentiation, and cancer. Cell Growth Differ., 3: 655-662, 1992.
2. Love, J. M., and Gudas, L. J. Vitamin A, differentiation and cancer. Curr. Opin. Cell Biol., 6: 825-831, 1994.
3. Lotan, R. Retinoids in cancer chemoprevention. FASEB J., 10: 1031-1039, 1996.
4. Hong, W. K., Lippman, S. M., Itiri, L. M., Karp, D. D., Lee, J. S., Byers, R. M., Schantz, S. P., Kramer, A. M., Lotan, R., Peters, L. J., Dimery, I. W., Brown, B. W., and Goepfert, H. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N. Engl. J. Med., 323: 795-801, 1990.
5. Lippman, S. M., Bataskis, J. G., Toth, B. B., Weber, R. S., Lee, J. J., Martin, J. W., Hays, G. L., Goepfert, H., and Hong, W. K. Comparison of low-dose isotretinoin with β-carotene to prevent oral carcinogenesis. N. Engl. J. Med., 328: 15-20, 1993.
6. Pastorino, U., Infante, M., Maioli, M., Chiesa, G., Buyse, M., Firket, P., Rosmentz, N., Clerici, M., Soresi, E., Valente, M., Belloni, P. A., and Ravasi, G. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J. Clin. Oncol., 11: 1216-1222, 1993.
7. Benner, S. E., Pajak, T. F., Lippman, S. M., and Hong, W. K. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J. Natl. Cancer Inst., 86: 140-141, 1994.
8. Chambon, P. The retinoid signalling pathway: molecular and genetic analyses. Semin. Cell Biol., 5: 115-125, 1994.
9. Chiesa, F., Tradati, N., Marazza, M., Rossi, N., Boracchi, P., Mariani, L., Clerici, M., Formelli, F., Barzan, L., and Carrassi, A. Prevention of local relapses and new localizations of oral leukoplakia with the synthetic retinoid fenretinide (4-HPR): preliminary results. Eur. J. Cancer, 28B: 97-102, 1994.
10. Hong, W. K., and Itri, L. M. Retinoids and human cancer. In: M. B. Sporn, A. B. Roberts, and D. S. Goodman (eds.), The Retinoids: Biology, Chemistry, and Medicine, pp. 597-658. New York: Raven Press, 1994.
11. Lippman, S. M., Benner, S. E., and Hong, W. K. Cancer chemoprevention. J. Clin. Oncol., 12: 851-873, 1994.
12. Meyskens, F. L., Surwit, E., Moon, T. E., Childers, J. M., Davis, J. R., Dorr, R. T., Johnson, C. S., and Alberts, D. S. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J. Natl. Cancer Inst., 86: 539-543, 1994.
13. Vokes, E. E., Weichselbaum, R. R., Lippman, S. M., and Hong, W. K. Head and neck cancer. N. Engl. J. Med., 328: 184-194, 1993.
14. Hunter, D. J., Manson, J. E., Colditz, G. A., Stampfer, M. J., Rosner, B., Hennekens, C. H., Speizer, F. E., and Willett, W. C. A prospective study of the intake of vitamins C, E, and A and the risk of breast cancer. N. Engl. J. Med., 329: 234-240, 1993.
15. Costa, A., De Palo, G., Decensi, A., Formelli, F., Chiesa, F., Nava, M., Camerini, T., Marubini, E., and Veronesi, U. Retinoids in cancer and chemoprevention. Clinical trials with the synthetic analogue fenretinide. Ann. N. Y. Acad. Sci., 768: 148-162, 1995.
16. De Palo, G., Veronesi, U., Marubini, E., Camerini, T., Chiesa, F., Nava, M., Formelli, F., Del Vecchio, M., Costa, A., and Boracchi, P. Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma, and oral leukoplakia. J. Cell. Biochem. Suppl., 22: 11-17, 1995.
17. Chambon, P. A decade of molecular biology of retinoic acid receptors. FASEB J., 10: 940-954, 1996.
18. Xu, X-C., Sneige, N., Liu, X., Nandagiri, R., Lee, J. J., Lukmanji, F., Hortoobagyi, G., Lippman, S. M., Dhingra, K., and Lotan, R. Progressive decrease in nuclear retinoic acid receptor β message RNA levels during breast carcinogenesis. Cancer Res., 57: 4992-4996, 1997.
19. Widschwendter, M., Berger, J., Daxenbichler, G., Muller-Holzner, E., Widschwendter, A., Mayr, A., Marth, C., and Zeimet, A. G. Loss of retinoic acid receptor expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res., 57: 4158-4161, 1997.
20. Deng, G., Lu, Y., Zlotnikov, G., Thor, A. D., and Smith, H. S. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science (Washington DC), 274: 2057-2059, 1996.
21. van der Berg, B., van der Leede, B-j., Kwakkenbos-Isbrucker, L., Salverda, S., de Laat, S. W., and van der Saag, P. T. Retinoic acid resistance of estradiol-independent breast cancer cell lines coincides with diminished retinoic acid receptor function. Mol. Cell. Endocrinol., 91: 149-157, 1993.
22. Swisshelm, K., Ryan, K., Lee, X., Tsou, H. C., Peacocke, M., and Sager, R. Down-regulation of a retinoic acid receptor-β in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells. Cell Growth Differ., 5: 133-141, 1994.
23. Seewaldt, V. L., Johnson, B. S., Parker, M. B., Collins, S. J., and Swisshelm, K. Expression of retinoic acid receptor β mediates retinoid-induced growth arrest and apoptosis in breast cancer cells. Cell Growth Differ., 6: 1077-1088, 1995.
24. 1 arrest but not apoptosis of normal human mammary epithelial cells. Cell Growth Differ., 8: 631-641, 1997.
25. Hong, W. K., and Sporn, M. B. Recent advances in the chemoprevention of cancer. Science (Washington DC), 278: 1073-1077, 1997.
26. Scheffner, M., Munger, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63: 1129-1136, 1990.
27. Wemess, B. A., Levine, J. A., and Howley, P. M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science (Washington DC), 248: 76-79, 1990.
28. Demers, G. W., Foster, S. A., Halbert, C. L., and Galloway, D. A. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci. USA, 91: 4382-4386, 1994.
29. Wazer, D. E., Liu, X-L., Chu, Q., Gao, Q., and Band, V. Immortalization of distinct human mammary epithelial cell types by human papilloma virus 16 E6 or E7. Proc. Natl. Acad. Sci. USA, 92: 3687-3691, 1995.
30. Wilcken, N. R., Sarcevic, B., Musgrove, E. A., and Sutherland, R. L. Differential effects of retinoids and antiestrogens on cell cycle progression and cell cycle regulatory genes in human breast cancer cells. Cell Growth Differ., 7: 65-74, 1996.
31. Watts, C. K. W., Brady, A., Sarcevic, B., de Fazio, A., Musgrove, E. A., and Sutherland, R. L. Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol. Endocrinol., 9: 1804-1813, 1995.
32. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
33. Riley, D. J., Lee, E. Y., and Lee, W-H. The retinoblastoma protein: more than a tumor suppressor. Annu. Rev. Cell Biol., 10: 1-29, 1994.
34. Hunter, T., and Pines, J. Cyclins and cancer. II. Cyclin D and cdk inhibitors come of age. Cell, 79: 573-582, 1994.
35. Morgan, D. O. Principles of CDK regulation. Nature (Lond.), 374: 131-134, 1995.
36. 1 phase progression: cycling on cue. Cell, 79: 551-555, 1994.
37. Sherr, C. J. Cancer cell cycles. Science (Washington DC), 274: 1672-1677, 1996.
38. Elledge, S. J. Cell cycle checkpoints: preventing an identity crisis. Science (Washington DC), 274: 1664-1672, 1996.
39. Demers, G. W., Espling, E., Harry, J. B., Etscheid, B. G., and Galloway, D. A. Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J. Virol., 70: 6862-6869, 1996.
40. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition of cell cycle arrest. Genes Dev., 8: 9-22, 1994.
41. 1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2. Mol. Cell. Biol., 16: 762-770, 1995.
42. 1-S-phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-cdk2. J. Biol. Chem., 272: 10882-10894, 1997.
43. Weinstat-Saslow, D., Merino, M. J., Manrow, R. E., Lawrence, J. A., Bluth, R. F., Wittenbel, K. D., Simpson, J. F., Page, D. L., and Steeg, P. S. Overexpression of cyclin D1 mRNA distinguishes invasive and in situ breast carcinomas from nonmalignant lesions. Nat. Med., 1: 1257-1260, 1995.
44. Alle, K. M., Henshall, S. M., Field, A. S., and Sutherland, R. L. Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin. Cancer Res., 4: 847-854, 1998.
45. 1 to complete the cell cycle. Proc. Natl. Acad. Sci. USA, 91: 8022-8026, 1994.
46. Zwijsen, R. M. L., Klompmaker, R., Wietjens, E., Kristel, P. M. P., van der Burg, B., and Michalides, R. J. A. M. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit. Mol. Cell. Biol., 16: 2554-2560, 1996.
47. Langenfield, J., Kiyokawa, H., Sekula, D., Boyle, J., and Dmitrovsky, E. Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc. Natl. Acad. Sci. USA, 94: 12070-12074, 1997.
48. Stampfer, M. Isolation and growth of human mammary epithelial cells. J. Tissue Cult. Methods, 9: 107-121, 1985.
49. Russell, W. C., Newman, C., and Williamson, D. H. A simple cytochemical technique for demonstration of DNA in cells infected with mycoplasmas and viruses. Nature (Lond.), 253: 461-462, 1975.